EPO in Medical Technology

Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients

...his period. One of the patients received his last epo injection more than 200 days ago. This is contras...the FDA approved standard regimen of thrice weekly epo injections, in which typical patients would expect...igned to produce and deliver a therapeutic dose of epo steadily for up to six months or more, EPODURE Bio...

XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma

...ting their proliferation and differentiation and maintaining their viability. Over the last decade, several reports have indicated that the action of epo is not restricted to the erythroid compartment, but may have additional biological, and consequently potential therapeutic properties, broadly beyond ...

Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease

...target range for four months without receiving any epo injections. By contrast, in standard practice today, epo injections are required up to several times per we...our months while alleviating the need for frequent epo injections. The Phase I/II clinical trial wa...

Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting

...alyses were performed using data through Week 44. The mean baseline estimated glomerular filtration rate was 30 mL/min/1.73 m2 and the median weekly epo doses (IU) were 4,382, 4,364 and 6,091 for TIW, QW and Q2W groups, respectively. For the TIW, QW and Q2W groups, the mean baseline Hb was 9.6, 9.7 and...

Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis

...ntrast to the improvement in fatigue of anemic cancer patients treated with epo which occurred only when anemia was also improved, Soliris-treated PNH pati...bin level increased as compared to anemic cancer patients treated with epo who experienced only a small improvement in fatigue (ES: +0.48). * ...

Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings

...t National Managed Care Database to examine recent epo and DARB treatment patterns and corresponding ...s in newly-initiated CKD patients treated with epo (n=1,110) or DARB (n=723) not receiving dialys...is chronic kidney disease population receiving epo (n=1,066) or DARB (n=375) through a pharmacy b...

Roche responds to announcement of 'IDEAL' hepatitis C trial results

... is often given to treat ribavirin-related anemia and help patients maintain a higher ribavirin dose. However, physicians could only prescribe epo after the first dose ribavirin reduction in the "IDEAL" trial. Since patients in the Peg- Intron arms generally had smaller ribavirin dose red...

Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs

... peptide (CTP) technology significantly increased the half-life of standard epo in animal models.(1) The study, which assessed an early version of EPO-CTP,...s effective in raising hematocrit levels as the same total dose of standard epo administered in three injections over the course of a week. The current ve...

Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients

...iting the upper threshold of hemoglobin levels to 11. Additionally, the FDA made it clear that the label instructions were never intended to result in epo doses being withheld if a patient's hemoglobin level exceeded 12. Further, the committee stressed the need for small incremental dose adjustments of E...

Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)

...ician selected regimens: best supportive care alone, low-dose cytarabine plus best supportive care or standard chemotherapy plus best supportive care. epo and prophylactic G-CSF use was not permitted. The CCR represented standard of care within the territories where the trial was conducted. The study eva...

Affymax Announces Results From Phase 2 Clinical Trial of Hematide for the Treatment of Anemia in Dialysis Patients

...y Ford Hospital, Detroit in a poster session at the NKF meeting. "These data are encouraging and show that patients can be switched from a regimen of epo three-times weekly to once monthly Hematide in a controlled fashion where hemoglobin levels were maintained within 1 g/dL of baseline at an appropriat...

Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin

...ietin with reported sales of $4.1 billion in 2006, out of a total estimated epo market size of $11.7 billion. Erythropoietin is prescribed for the treatmen...II clinical trial, and Modigene's human growth hormone, interferon beta and epo in pre-clinical models, the CTP platform is gaining credibility as having t...

Hemoglobin Testing at the Point of Care

... corrects for lipemia, leukocytosis and other sources of turbidity. Capillary, venous or arterial blood samples can be used, so transfusion decisions, epo dosing and anemia screenings can be performed immediately and at the point of care. Both systems are CLIA waived and the B-Hemoglobin photometer is av...